- Abiomed Inc's ABMD Restore EF study demonstrated that Impella-supported high-risk percutaneous coronary intervention (PCI) leads to significant improvements in left ventricular ejection fraction (LVEF), angina symptoms, and heart failure symptoms at follow-up.
- A 29% relative improvement from baseline LVEF (n=251, p<0.0001), with a significantly greater improvement in LVEF for those who had complete revascularization.
- Significant improvement in heart failure symptoms was observed, with an overall 76% reduction in heart failure symptoms.
- Significant improvement in angina symptoms, with an overall 97% reduction in angina symptoms.
- Participants with higher baseline LVEF (greater than 45%) also experienced significant symptomatic improvement, similar to patients with lower LVEF.
- Restore EF and the PROTECT III study further demonstrate the safety and benefits.
- PROTECT III shows reduced MACCE rates compared to PROTECT II (15.1% vs. 21.9%) when Impella is used to achieve more complete revascularization in a single setting for high-risk PCI patients.
- Operators from the community and academic centers demonstrated low major bleeding rates of 2.5% in the Restore EF study and 1.8% in the PROTECT III study when contemporary best practices were followed.
- Price Action: ABMD shares are down 1.41% at $290.90 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in